查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004915

被忽視的熱帶疾病診斷市場：按技術、疾病類型和最終用戶分類－2026-2032年全球預測

Neglected Tropical Diseases Diagnosis Market by Technology, Disease Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

被忽視的熱帶疾病診斷市場預計到 2025 年將達到 74.7 億美元，到 2026 年將成長到 79.4 億美元，到 2032 年將達到 112.7 億美元，複合年成長率為 6.05%。

主要市場統計數據
基準年 2025 74.7億美元
預計年份：2026年 79.4億美元
預測年份 2032 112.7億美元
複合年成長率 (%) 6.05%

對被忽視的熱帶疾病的診斷進行背景解釋，將其置於全球衛生優先事項和實際情況的背景下，以便指南戰略決策。

被忽視的熱帶疾病（NTDs）在許多中低收入國家仍然是持續存在的公共衛生挑戰，為衛生系統和發展夥伴帶來了複雜的診斷難題。 NTDs的診斷策略必須在敏感性和特異性需求與基礎設施、人力資源能力和供應鏈韌性等限制因素之間取得平衡。隨著全球衛生相關人員轉向疾病綜合管理和根除目標，診斷正變得至關重要，它既是進行臨床診療的手段，也是計畫決策的監測工具。

對不同衛生系統中被忽視的熱帶疾病診斷的關鍵技術、監管、規劃和採購變化進行分析。

由於技術、計畫和政策等多方面因素的共同作用，被忽視的熱帶疾病（NTD）的診斷格局正在經歷多項變革。分子生物學的創新、儀器的微型化以及數位連接的普及降低了部分技術壁壘，使得在分散的環境中也能進行更靈敏的檢測。同時，人們越來越重視支持多病種篩檢和監測的綜合診斷，這反映了醫療保健系統向更高效的模式和資源最佳化轉型的大趨勢。

本文探討了貿易政策和關稅壓力的變化如何改變診斷設備的籌資策略、供應鏈的韌性以及專案永續性。

近期主要市場貿易政策和關稅結構的變化為診斷供應鏈帶來了新的成本考量，影響試劑、耗材和診斷硬體的籌資策略。進口關稅和海關程序的變化不僅會影響到貨成本，還會影響採購週期的靈活性。這在需要快速擴大專案規模時至關重要，例如應對感染疾病疫情或大規模藥物管理宣傳活動。關稅法規與區域生產能力之間的相互作用是供應商決定生產本地化和庫存儲存地點的關鍵因素。

基於全面細分的洞察，將診斷技術、疾病特定需求、最終用戶背景、應用和檢體類型與部署優先事項關聯起來。

對技術、疾病類型、最終用戶、應用和檢體類型等細分市場的深入理解，揭示了創新和推廣的清晰路徑。在技​​術領域，免疫檢測（包括化學冷光和酵素免疫分析法(ELISA)）在血清學監測和確診檢測中仍然發揮著重要作用，而顯微鏡技術（包括螢光和光學顯微鏡）在許多情況下仍然是低成本診斷的基礎手段。分子診斷技術，例如聚合酵素鏈鎖反應(PCR) 和等溫擴增，對低寄生蟲負荷的感染疾病具有高靈敏度，並在確診過程中發揮越來越重要的作用。快速診斷測試（包括抗原檢測和抗體檢測）為社區篩檢和臨床決策提供了所需的便利性和速度。

美洲、歐洲、中東和非洲以及亞太地區的規劃和營運趨勢決定了診斷的取得和實施方案。

區域趨勢持續影響專案優先事項、診斷獲取途徑和產品部署路徑。在美洲，都市區差距以及局部流行區的存在，使得將三級醫療機構的實驗室診斷能力與遠距快速篩檢工具相結合成為推廣，重點在於將被忽視的熱帶疾病（NTD）診斷納入更廣泛的基層醫療服務。跨境合作和地方公共衛生舉措正在影響集中採購和數據共用實踐，以支持有針對性的根除計劃。

深入了解被忽視的熱帶疾病 (NTD) 診斷領域的競爭格局、合作夥伴關係和產品差異化策略。

被忽視的熱帶疾病（NTD）診斷領域的競爭格局由成熟的診斷公司、專注於特定領域的研發公司、學術實驗室以及支持檢驗和臨床評估的受託研究機構組成。成熟公司正在調整其產品組合，以滿足對整合檢測解決方案和數位化連接的需求，而小規模的創新者則傾向於專注於顛覆性平台，例如簡化的等溫擴增、新型抗原檢測化學以及專為現場部署而設計的無需儀器的讀取器。

為製造商、資助者和專案規劃者提供實用建議，使診斷技術的創新與現場部署和專案永續性。

產業領導者應採取務實且多管齊下的方法，使創新與實際部署相契合。首先，優先發展穩健、易用且最大限度減少對複雜低溫運輸和精密基礎設施依賴的研發路徑，從而擴大診斷技術有效部署的環境範圍。其次，投資進行檢驗研究，以證明其在專案實施環境中以及所有相關檢體類型中的表現，從而建立採購機構和第一線醫護人員的信任。

為了支持所提出的研究結果，我們將清楚地解釋混合方法研究途徑，該方法結合了相關人員訪談、文獻整合和比較分析。

本報告整合了一手和二手研究資料，結合相關人員訪談、產品性能文獻、監管指導文件和實地檢驗研究，對研究結果進行了多角度的檢驗。一手資料包括對診斷方法開發人員、實驗室管理人員、流行地區臨床醫生、採購專家和公共衛生專案管理人員的結構化訪談，這些訪談提供了關於可用性、供應鏈考量和推廣障礙的定性觀點。二手資料包括關於診斷性能的同行評審文獻、公開的監管標準以及全球衛生當局關於實施被忽視的熱帶病（NTD）項目的技術指導。

策略結論強調可操作的創新、夥伴關係以及採購系統的調整，以此作為改善診斷技術和永續公共衛生成果的途徑。

診斷技術在推動被忽視的熱帶疾病（NTD）防治工作中發揮核心作用，對個別患者照護和人群層面的計畫目標均有貢獻。技術進步、採購慣例的轉變以及對監測日益重視，為彌合數十年來診斷方面的差距創造了契機。為了充分發揮這一潛力，研發人員、資助者、專案實施者和監管機構必須攜手合作，確保產品從實用化走向實際應用，同時優先考慮易用性、品質和供應鏈的韌性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：被忽視的熱帶疾病診斷市場：依技術分類

  • 免疫檢測
    • 化學冷光
    • 酵素免疫分析法
  • 顯微鏡檢查
    • 螢光顯微鏡
    • 光學顯微鏡
  • 分子診斷
    • 等溫擴增
    • 聚合酵素鏈鎖反應
  • 快速診斷測試
    • 抗體檢測
    • 抗原檢測

第9章：被忽視的熱帶疾病診斷市場：依疾病類型分類

  • 南美錐蟲病
    • 酵素免疫分析法
    • 聚合酵素鏈鎖反應
  • 利什曼原蟲症
    • 皮膚利什曼原蟲症檢測
    • 利什曼原蟲症檢測
  • 淋巴絲蟲病
    • 抗體檢測
    • 層析法
  • 盤尾絲蟲病
    • 聚合酵素鏈鎖反應
    • 皮膚SNI顯微鏡
  • 血吸蟲病
    • 糞便顯微鏡檢查
    • 尿抗原檢測

第10章：被忽視的熱帶疾病診斷市場：以最終用戶分類

  • 診所
    • 社區健康中心
    • 基層醫療診所
  • 診斷檢查室
    • 獨立檢測實驗室
    • 測試承包組織
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究機構

第11章：被忽視的熱帶疾病診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：被忽視的熱帶疾病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：被忽視的熱帶疾病診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國被忽視的熱帶疾病診斷市場

第15章：中國被忽視的熱帶疾病診斷市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Anitoa Systems, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Coris BioConcept SPRL
  • DiaSys Diagnostic Systems GmbH
  • F. Hoffmann-La Roche Ltd
  • Genome Diagnostics Pvt. Ltd.
  • Hologic, Inc.
  • InBios International, Inc.
  • Johnson & Johnson Services, Inc.
  • Meridian Bioscience, Inc.
  • Novartis AG
  • Omega Diagnostics Group plc
  • Oscar Medicare Pvt. Ltd.
  • QIAGEN NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • ZeptoMetrix Corporation
Product Code: MRR-742BD5181EB6

The Neglected Tropical Diseases Diagnosis Market was valued at USD 7.47 billion in 2025 and is projected to grow to USD 7.94 billion in 2026, with a CAGR of 6.05%, reaching USD 11.27 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.47 billion
Estimated Year [2026] USD 7.94 billion
Forecast Year [2032] USD 11.27 billion
CAGR (%) 6.05%

Contextual introduction that situates neglected tropical diseases diagnostics within global health priorities and operational realities to guide strategic decision making

Neglected tropical diseases (NTDs) remain a persistent public health challenge in many low- and middle-income settings, placing complex diagnostic demands on health systems and development partners. Diagnostic strategies for NTDs must reconcile the need for sensitivity and specificity with constraints in infrastructure, workforce capacity, and supply chain resilience. As global health actors pivot toward integrated disease management and elimination goals, diagnostics assume a central role both as enablers of clinical care and as surveillance instruments for programmatic decision-making.

This executive summary synthesizes current diagnostic technology trends, disease-specific testing pathways, end-user dynamics, and regional programmatic drivers that shape the evolving landscape. The intent is to provide healthcare leaders, diagnostic developers, procurement agencies, and policy makers with a concise yet comprehensive analytical foundation to support strategic planning. By framing diagnostic innovation alongside operational realities, the summary highlights where technological advances, policy shifts, and financing mechanisms intersect to accelerate-or in some cases impede-progress against NTDs.

The content emphasizes practical implications for stakeholders who must balance diagnostic performance with affordability, accessibility, and sustainability. It also underscores the interplay between point-of-care approaches and centralized laboratory confirmation, illustrating how diverse testing modalities contribute differently to case detection, surveillance, and program validation across varied epidemiological contexts.

Analysis of the pivotal technological, regulatory, programmatic, and procurement shifts reshaping diagnostics for neglected tropical diseases across diverse health systems

The diagnostic landscape for NTDs is undergoing several transformative shifts driven by converging technological, programmatic, and policy forces. Innovations in molecular biology, miniaturized instrumentation, and digital connectivity have lowered some technical barriers, enabling more sensitive assays to be used in decentralized settings. At the same time, there is an increasing emphasis on integrated diagnostics that support multi-disease screening and surveillance, reflecting a broader push for health system efficiencies and resource optimization.

Regulatory evolution and quality assurance frameworks are also reshaping product pathways. Greater attention to validation in real-world contexts, along with calls for harmonized performance standards, is prompting manufacturers and developers to design assays that meet both laboratory and point-of-care expectations. Procurement behaviors are shifting toward outcome-based and pooled purchasing mechanisms, encouraging suppliers to align product portfolios with programmatic needs rather than purely laboratory-driven specifications.

Operationally, community-level programs are demanding tests that are rapid, robust under field conditions, and deliver clear actionable outputs for frontline workers. Simultaneously, centralized laboratories continue to require high-throughput, confirmatory platforms to validate cases and support elimination verification. These dual imperatives are driving hybrid strategies that pair on-site screening with confirmatory laboratory workflows, supported by digital reporting chains that enable faster public health action and improved surveillance granularity.

Examination of how evolving trade policies and tariff pressures are altering diagnostic sourcing strategies, supply chain resilience, and procurement trade-offs for program sustainability

Recent shifts in trade policy and tariff structures in major markets have introduced new cost considerations into diagnostic supply chains, affecting sourcing strategies for reagents, consumables, and diagnostic hardware. Changes to import duties and customs practices can influence not only landed costs but also the agility of procurement cycles, which are critical when programs require rapid scale-up during outbreak responses or mass drug administration campaigns. The interplay between tariff rules and regional manufacturing capacity has become an important determinant of where suppliers choose to localize production or stock inventory.

For program planners and procurement officers, the practical implication is a reassessment of supplier portfolios and an increased focus on supply chain redundancy. Organizations are evaluating the trade-offs between single-source procurement of validated products and diversified sourcing that mitigates tariff-driven price volatility or border-related delays. In some cases, increased tariffs have accelerated conversations about regional manufacturing partnerships and technology transfer models that can insulate programs from future policy shocks.

Operationally, tariff-induced cost pressures tend to magnify the advantage of diagnostic approaches that minimize recurring imports, such as assays with longer shelf-lives, reduced cold-chain dependence, or platforms compatible with locally produced consumables. As a result, stakeholders are reexamining test selection criteria with supply chain resilience and total cost of ownership in mind, favoring solutions that balance diagnostic performance with pragmatic logistics under evolving trade conditions.

Comprehensive segmentation-driven insights that map diagnostic technologies, disease-specific needs, end-user contexts, applications, and sample types to implementation priorities

A nuanced understanding of segmentation across technology, disease type, end user, application, and sample type reveals distinct pathways for innovation and implementation. In the technology domain, immunoassays-encompassing chemiluminescence assays and enzyme-linked immunosorbent assays-remain important for serological surveillance and confirmatory testing, while microscopy approaches, including fluorescence and light microscopy, continue to serve as low-cost diagnostic backbones in many settings. Molecular diagnostics, represented by polymerase chain reaction and isothermal amplification methods, offer high sensitivity for low-parasite-burden infections and play an increasingly central role in confirmation workflows. Rapid diagnostic tests, with both antigen and antibody detection formats, provide the speed and simplicity required for community screening and point-of-care decision-making.

Disease-specific diagnostics show differentiated needs that shape product development and deployment. Chagas diagnostics frequently pair enzyme-linked immunosorbent assay and polymerase chain reaction to address both chronic serology and acute parasitemia detection, whereas leishmaniasis diagnostics bifurcate into tests optimized for cutaneous and visceral presentations. Lymphatic filariasis relies heavily on antibody detection tests alongside immunochromatographic approaches for mass screening, while onchocerciasis often requires polymerase chain reaction and skin snip microscopy methods depending on program stage. Schistosomiasis testing strategies blend stool microscopy concentration techniques with urine antigen assays to accommodate community-level mapping and individual case confirmation.

End-user contexts strongly influence acceptable product attributes. Clinics and primary care settings prioritize ease of use and minimal infrastructure requirements, community health centers need durable tests suited for outreach, diagnostic laboratories demand standardized protocols and traceability, and hospitals-both private and public-require integration with clinical workflows and laboratory information systems. Research institutes further drive innovation by evaluating novel biomarkers and validation protocols. Applications range from confirmatory laboratory and point-of-care confirmation to community screening approaches that support mass drug administration, and surveillance activities that span epidemiological monitoring through to post-elimination vigilance. Sample type considerations-blood in serum, plasma or whole blood formats, stool through concentration or direct smear, tissue from biopsies or skin snips, and urine via concentrated or direct testing-determine pre-analytical workflows and influence test design choices such as input volumes, preservation requirements, and biosafety implications.

Taken together, segmentation insights highlight where manufacturers can differentiate offerings by aligning technology platforms with disease-specific performance needs, by tailoring workflows to end-user capacity, and by optimizing sample handling to suit programmatic realities. This segmentation-driven lens helps stakeholders prioritize investments that close diagnostic gaps while ensuring practical deployability across diverse operational environments.

Regional programmatic and operational dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine diagnostic access and implementation choices

Regional dynamics continue to shape programmatic priorities, diagnostic accessibility, and product adoption pathways. In the Americas, urban-rural disparities and pockets of endemicity require a blend of laboratory confirmation capacity in tertiary centers and rapid screening tools for remote outreach, with an emphasis on integrating NTD diagnostics into broader primary care services. Cross-border coordination and regional public health initiatives influence procurement harmonization and data sharing practices that support targeted elimination programs.

Europe, Middle East & Africa presents a heterogeneous landscape where some countries possess advanced laboratory infrastructure while others face significant resource constraints. This region's priorities often include strengthening laboratory networks, building quality assurance systems, and enabling decentralized diagnostics that can function with intermittent power and limited cold-chain capacity. Regulatory environments and fragmented procurement mechanisms in parts of the region make harmonized validation and pooled purchasing attractive options for reducing duplicative costs and improving access.

Asia-Pacific exhibits a wide spectrum of epidemiological contexts, from densely populated urban centers to remote island communities. Program strategies here emphasize scalable screening modalities, integration with other endemic disease programs, and investments in local manufacturing capacity to shorten supply chains. The region's growing diagnostic manufacturing footprint and increasing public-private collaboration present opportunities to adapt technologies for both high-volume surveillance and sensitive case confirmation in low-transmission settings.

Insights into the competitive landscape, collaborative partnerships, and product differentiation strategies shaping the neglected tropical diseases diagnostics sector

The competitive ecosystem for NTD diagnostics includes a mix of established diagnostics manufacturers, specialized niche developers, academic laboratories, and contract research organizations that support validation and clinical evaluation. Established firms are adapting portfolios to address the need for integrated testing solutions and digital connectivity, while smaller innovators often focus on disruptive platforms such as simplified isothermal amplification, novel antigen detection chemistries, and instrument-free readouts designed for field deployment.

Collaborations between commercial entities and academic research centers accelerate translation of novel biomarkers into deployable assays, and partnerships with non-governmental organizations and global health donors help pilot products in real-world program settings. Contract development and manufacturing organizations play a critical role in scaling production and ensuring quality systems compliance, particularly for late-stage validation and prequalification. Procurement entities increasingly expect suppliers to demonstrate robust post-market surveillance and support mechanisms for training, quality control, and supply continuity.

For companies seeking to differentiate, investment in usability testing, end-user training materials, and digital integration capabilities can create competitive advantage. Similarly, strategic alliances that enable regional manufacturing or in-country assembly can mitigate supply chain disruption and improve access in markets where localization reduces logistical friction and supports program sustainability.

Actionable recommendations for manufacturers, funders, and program planners to align diagnostic innovation with field deployment realities and program sustainability

Industry leaders should adopt a pragmatic, multi-pronged approach that aligns innovation with implementation realities. First, prioritize development pathways that emphasize robustness, ease of use, and minimal reliance on complex cold chains or sophisticated infrastructure, thereby expanding the range of settings where diagnostics can be effectively deployed. Second, invest in validation studies that demonstrate performance in programmatic conditions and across relevant sample types to build confidence among procurement agencies and frontline providers.

Third, cultivate regional manufacturing or assembly partnerships to reduce exposure to cross-border trade disruptions and to shorten lead times for consumables and instruments. Fourth, design pricing and distribution models that reflect the total cost of ownership, including training, quality assurance, and maintenance, and engage early with procurement stakeholders to align product specifications with program budgets and policy frameworks. Fifth, incorporate digital reporting capabilities that streamline data flows from peripheral testing sites to central surveillance systems, enabling faster public health responses and more efficient program monitoring.

Finally, adopt collaborative commercialization strategies that include partnerships with non-governmental organizations, governmental programs, and research institutes to facilitate field evaluations, user feedback loops, and phased roll-outs that inform product iteration. By executing on these priorities, industry leaders can ensure that investments in technology translate into measurable improvements in case detection, surveillance quality, and programmatic impact.

Clear explanation of the mixed-methods research approach combining stakeholder interviews, literature synthesis, and comparative analysis to underpin the insights presented

This report synthesizes primary and secondary research, combining stakeholder interviews, product performance literature, regulatory guidance documents, and field validation studies to triangulate insights. Primary inputs include structured interviews with diagnostic developers, laboratory directors, clinicians in endemic settings, procurement specialists, and public health program managers, which provided qualitative perspectives on usability, supply chain considerations, and adoption barriers. Secondary sources comprised peer-reviewed literature on diagnostic performance, publicly available regulatory standards, and technical guidance from global health authorities related to NTD program implementation.

Analytical methods included cross-segmentation mapping to identify alignment and gaps between technology attributes and end-user needs, scenario analysis to assess supply chain and procurement sensitivities, and comparative assessment of diagnostic workflows across disease-specific contexts. Where available, real-world validation data and field study outcomes informed assessments of operational suitability. The methodology prioritized transparency by documenting data provenance, interview protocols, and criteria used for technology and product evaluation, enabling reproducibility and informed follow-up research.

Limitations include variability in published performance data across settings and the evolving nature of regulatory pathways, which require ongoing monitoring. Nonetheless, the mixed-methods approach provides a robust foundation for strategic decision-making by combining empirical evidence with practical stakeholder perspectives drawn from diverse geographic and institutional contexts.

Strategic conclusion emphasizing pragmatic innovation, partnerships, and procurement alignment as the pathway to improved diagnostics and durable public health gains

Diagnostics are central to progress against neglected tropical diseases, serving both individual patient care and population-level program objectives. The convergence of technological advances, shifting procurement practices, and heightened emphasis on surveillance creates a window of opportunity to close diagnostic gaps that have persisted for decades. Realizing this potential requires coordinated action across developers, funders, program implementers, and regulatory bodies to ensure that products move from innovation to deployment with attention to usability, quality, and supply chain resilience.

Strategic investments in regionally appropriate technologies, validation in programmatic contexts, and mechanisms that de-risk local manufacturing will accelerate access and sustainability. Moreover, integrated approaches that combine rapid screening at the community level with confirmatory laboratory workflows and strengthened data systems will enhance detection sensitivity while supporting timely public health interventions. The cumulative effect of these steps will be measurable improvements in case finding, surveillance fidelity, and the ability to validate elimination milestones in endemic regions.

Ultimately, the path forward is one of pragmatic innovation: technologies that meet field realities, partnerships that bridge development and delivery, and procurement strategies that emphasize reliability and total cost considerations. Stakeholders who align their initiatives with these principles will be best positioned to translate diagnostic advances into durable public health gains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neglected Tropical Diseases Diagnosis Market, by Technology

  • 8.1. Immunoassays
    • 8.1.1. Chemiluminescence Assay
    • 8.1.2. Enzyme Linked Immunosorbent Assay
  • 8.2. Microscopy
    • 8.2.1. Fluorescence Microscopy
    • 8.2.2. Light Microscopy
  • 8.3. Molecular Diagnostics
    • 8.3.1. Isothermal Amplification
    • 8.3.2. Polymerase Chain Reaction
  • 8.4. Rapid Diagnostic Tests
    • 8.4.1. Antibody Detection
    • 8.4.2. Antigen Detection

9. Neglected Tropical Diseases Diagnosis Market, by Disease Type

  • 9.1. Chagas Disease
    • 9.1.1. Enzyme Linked Immunosorbent Assay
    • 9.1.2. Polymerase Chain Reaction
  • 9.2. Leishmaniasis
    • 9.2.1. Cutaneous Leishmaniasis Tests
    • 9.2.2. Visceral Leishmaniasis Tests
  • 9.3. Lymphatic Filariasis
    • 9.3.1. Antibody Detection Test
    • 9.3.2. Immunochromatographic Test
  • 9.4. Onchocerciasis
    • 9.4.1. Polymerase Chain Reaction
    • 9.4.2. Skin Snip Microscopy
  • 9.5. Schistosomiasis
    • 9.5.1. Stool Microscopy
    • 9.5.2. Urine Antigen Test

10. Neglected Tropical Diseases Diagnosis Market, by End User

  • 10.1. Clinics
    • 10.1.1. Community Health Centers
    • 10.1.2. Primary Care Clinics
  • 10.2. Diagnostic Laboratories
    • 10.2.1. Independent Laboratories
    • 10.2.2. Reference Laboratories
  • 10.3. Hospitals
    • 10.3.1. Private Hospitals
    • 10.3.2. Public Hospitals
  • 10.4. Research Institutes

11. Neglected Tropical Diseases Diagnosis Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Neglected Tropical Diseases Diagnosis Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Neglected Tropical Diseases Diagnosis Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Neglected Tropical Diseases Diagnosis Market

15. China Neglected Tropical Diseases Diagnosis Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Agilent Technologies, Inc.
  • 16.7. Anitoa Systems, Inc.
  • 16.8. Becton, Dickinson and Company
  • 16.9. bioMerieux SA
  • 16.10. Coris BioConcept SPRL
  • 16.11. DiaSys Diagnostic Systems GmbH
  • 16.12. F. Hoffmann-La Roche Ltd
  • 16.13. Genome Diagnostics Pvt. Ltd.
  • 16.14. Hologic, Inc.
  • 16.15. InBios International, Inc.
  • 16.16. Johnson & Johnson Services, Inc.
  • 16.17. Meridian Bioscience, Inc.
  • 16.18. Novartis AG
  • 16.19. Omega Diagnostics Group plc
  • 16.20. Oscar Medicare Pvt. Ltd.
  • 16.21. QIAGEN N.V.
  • 16.22. Siemens Healthineers AG
  • 16.23. Thermo Fisher Scientific Inc.
  • 16.24. ZeptoMetrix Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS